Tag: Jiangsu Hengrui Pharmaceuticals Co.

Merck Will Pay Up to $2 Billion for Chinese Heart Drug Rights

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.